Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation

Low-grade serous ovarian cancer (LGSOC) is now considered a different entity from high-grade serous ovarian cancer. The chemoresistance inherent to this type of ovarian cancer narrows the therapeutic options, especially in the recurrent setting. It is thought that the mitogen-activated protein kinas...

Полное описание

Библиографические подробности

Главные авторы:	Bárbara Lima, Miguel Henriques Abreu, Susana Sousa, Carla Bartosch, Deolinda Pereira
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2022-04-01
Серии:	Gynecologic Oncology Reports
Предметы:	Low-grade serous ovarian cancer BRAF mutation Dabrafenib Trametinib Combination treatment
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2352578922000224
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!